Sildenafil Pediatric (Under 12) Dosing

Sildenafil Has No Pediatric Indication for Erectile Dysfunction

Sildenafil was first approved in 1998 for erectile dysfunction in adult men based on the landmark Goldstein et al. trial, which randomized 532 men and demonstrated significant improvements in erectile function scores across all sildenafil dose groups compared to placebo 1. That approval applies exclusively to adults.

No clinical trial has studied sildenafil for erectile dysfunction in children. The drug's ED indication (marketed as Viagra) carries labeling restricted to men aged 18 and older. Prescribing sildenafil for ED in a patient under 12 would be off-label, unsupported by evidence, and clinically inappropriate. Pediatric erectile function develops during puberty, and prepubertal children do not present with erectile dysfunction as a treatable condition.

The only scenario where a child under 12 receives sildenafil is pulmonary arterial hypertension. The rest of this article addresses that indication exclusively. Parents who encounter sildenafil on their child's medication list should understand that the drug is being used for a serious cardiovascular condition, not for any sexual health purpose.

The Pediatric PAH Indication: Why Children Receive Sildenafil

Sildenafil relaxes pulmonary vascular smooth muscle by inhibiting phosphodiesterase type 5 (PDE5), an enzyme that breaks down cyclic guanosine monophosphate (cGMP) in the lung vasculature. In children with PAH, elevated pulmonary artery pressure strains the right ventricle, and reducing that pressure can improve exercise tolerance, oxygen saturation, and survival 2.

Pediatric PAH is rare. The estimated prevalence in children is 2 to 16 cases per million, according to registry data from the Netherlands and the United Kingdom 3. Despite its rarity, PAH in children carries significant mortality: historical 5-year survival rates ranged from 35% to 55% before modern targeted therapies became available 4.

Sildenafil became one of the first targeted PAH therapies studied in a large pediatric population. Before the STARTS trials, clinicians prescribed it based on adult PAH data and small case series. That changed in 2012.

The STARTS-1 Trial: Establishing Efficacy

The Sildenafil in Treatment-Naive Children, Aged 1 to 17 Years, with Pulmonary Arterial Hypertension (STARTS-1) trial enrolled 235 children with PAH across 33 countries 2. It was a randomized, double-blind, placebo-controlled, dose-ranging study. Children received low, medium, or high doses of oral sildenafil, or placebo, for 16 weeks.

Results were mixed. The primary endpoint, change in peak oxygen consumption (VO2) during cardiopulmonary exercise testing, did not reach statistical significance. But a secondary analysis showed a statistically significant improvement in mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance index across all dose groups. The medium and high doses produced greater hemodynamic improvements than the low dose.

STARTS-1 confirmed that sildenafil lowers pulmonary pressures in children. It did not establish a clear dose-response for functional exercise capacity, a discrepancy that became important when long-term data emerged.

STARTS-2: The Mortality Signal That Changed Dosing

All STARTS-1 participants who completed 16 weeks were eligible for STARTS-2, the open-label extension study. During a median follow-up of approximately 3 years, a dose-dependent increase in mortality was observed 5.

Children randomized to the high-dose group in STARTS-1 (and who continued on high doses in STARTS-2) had higher mortality than those on low doses. Across the entire cohort, 37 of 235 patients died during the combined observation period. The hazard ratio for death in the high-dose group versus the low-dose group was 3.5, a finding that prompted regulatory action on both sides of the Atlantic.

The mechanism behind dose-dependent mortality remains debated. One hypothesis involves systemic hypotension from excessive PDE5 inhibition in a population already prone to low cardiac output. Another points to possible pro-arrhythmic effects at high exposure levels. Regardless of the explanation, the clinical signal was strong enough to change practice.

The 2012 FDA Safety Communication

On August 30, 2012, the FDA issued a Drug Safety Communication recommending against the use of Revatio (sildenafil) in children ages 1 to 17 for PAH 6. The initial statement was broadly worded, and many clinicians interpreted it as a contraindication for all pediatric sildenafil use.

In March 2014, the FDA clarified its position 7. The updated guidance stated that low doses of sildenafil may be acceptable in children with PAH but that high doses (defined as doses exceeding the recommended range) should not be used. The FDA also updated the Revatio label to include pediatric dosing information and the mortality warning.

Dr. Ellis Unger, then Director of the FDA's Office of Drug Evaluation I, stated in the 2014 clarification: "We want physicians to understand that we are not saying sildenafil should never be used in children with PAH. We are saying that high doses appear to increase the risk of death and should be avoided."

Weight-Based Dosing in Children Under 12

Pediatric sildenafil dosing for PAH is weight-based. The FDA-approved labeling for Revatio provides the following oral dosing for children aged 1 year and older 7:

Children weighing 8 kg to 20 kg: 10 mg orally three times daily.

Children weighing greater than 20 kg: 20 mg orally three times daily.

These doses align with the "low dose" arm of STARTS-1 (approximately 0.5 to 1 mg/kg per dose). The European Medicines Agency (EMA) approved similar weight-based bands for pediatric PAH in 2011, making the EU one of the first regulatory jurisdictions to formally include pediatric PAH on the sildenafil label 8.

For infants and neonates (under 1 year), no FDA-approved dose exists. Off-label use in neonatal persistent pulmonary hypertension of the newborn (PPHN) typically begins at 0.5 mg/kg every 6 to 8 hours, titrated based on hemodynamic response and tolerability 9. This use remains investigational.

The oral suspension formulation (Revatio 10 mg/mL) allows precise dosing by syringe for small children. Tablets can be used in older children who can swallow them, but splitting 20 mg tablets to achieve a 10 mg dose introduces dosing inaccuracy and is not recommended when the suspension is available.

Monitoring and Safety Considerations for Children

Children receiving sildenafil for PAH require structured follow-up. The 2015 American Heart Association/American Thoracic Society pediatric pulmonary hypertension guidelines recommend the following monitoring framework 10:

Hemodynamic monitoring. Baseline right heart catheterization before starting therapy, with repeat catheterization at 3 to 12 months depending on clinical trajectory. Echocardiography every 3 to 6 months to track right ventricular function and tricuspid regurgitant jet velocity.

Growth and development. Weight, height, and developmental milestones at each visit. PAH-related failure to thrive is common in children, and sildenafil's hemodynamic improvements can sometimes unmask nutritional deficits that need independent attention.

Hepatic function. Liver enzymes at baseline and periodically during therapy. Sildenafil undergoes extensive hepatic metabolism via CYP3A4 and CYP2C9, and children with hepatic impairment may achieve supratherapeutic plasma levels at standard doses.

Visual and auditory screening. PDE5 has low-level expression in the retina (PDE6 cross-reactivity) and inner ear. Reports of visual disturbance and sudden hearing loss exist in adult sildenafil users. The AHA/ATS guidelines recommend baseline ophthalmologic evaluation and periodic screening in children, particularly those on long-term therapy.

Blood pressure monitoring. Sildenafil can cause systemic hypotension. Standing and supine blood pressures should be recorded at each visit, and parents should be counseled on symptoms of orthostatic lightheadedness.

Drug Interactions in Pediatric Patients

Several drug interactions are clinically significant in children receiving sildenafil for PAH.

Nitrates are absolutely contraindicated. Co-administration causes profound and potentially fatal hypotension. This is less commonly encountered in pediatric PAH than in adult practice but remains relevant for children who may receive nitroglycerin in surgical or emergency settings 1.

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) increase sildenafil plasma levels by 2- to 11-fold. In the STARTS population, co-administration of bosentan (a CYP3A4 inducer) reduced sildenafil levels by approximately 50%, which led some investigators to use higher sildenafil doses in bosentan-treated children 11. After the STARTS-2 mortality signal, this practice requires careful risk-benefit discussion.

Concurrent use with other PAH-targeted therapies (bosentan, ambrisentan, epoprostenol, treprostinil) is common in pediatric practice. Combination therapy is supported by the 2015 AHA/ATS guidelines for children with inadequate response to monotherapy, though the evidence base is smaller than in adults 10.

Discontinuation Risks: Rebound Pulmonary Hypertension

Abrupt sildenafil withdrawal in children with PAH can precipitate rebound pulmonary hypertension, a sudden and dangerous spike in pulmonary pressures that can cause right ventricular failure and death 12. This risk applies to all durations of therapy but is most pronounced in children who have been on sildenafil for months or years.

The AHA/ATS guidelines recommend gradual dose tapering over weeks when discontinuation is planned, with close hemodynamic monitoring during and after the taper 10. If a child is transitioning from sildenafil to another PAH therapy, overlap periods should be used rather than sequential withdrawal and initiation.

Parents and caregivers must understand the importance of medication adherence. Missed doses, insurance lapses, or pharmacy shortages can create unintentional gaps that carry rebound risk. A 2016 survey of pediatric PAH centers found that 23% of programs had encountered at least one case of rebound hypertension related to unplanned sildenafil interruption 12.

Neonatal PPHN: An Off-Label But Common Use

Persistent pulmonary hypertension of the newborn (PPHN) affects approximately 2 per 1,000 live births 13. Inhaled nitric oxide (iNO) is the first-line pulmonary vasodilator for PPHN, but sildenafil is frequently used when iNO is unavailable, when the neonate fails to respond to iNO, or during iNO weaning.

A 2017 Cochrane review evaluated sildenafil for PPHN and found limited but suggestive evidence of benefit, including improvements in oxygenation index and reductions in mortality in resource-limited settings where iNO is not accessible 14. The review noted high risk of bias in most included studies and called for larger randomized trials.

Neonatal dosing typically starts at 0.5 mg/kg enterally every 6 to 8 hours, though some centers use 1 mg/kg per dose. Intravenous sildenafil (0.1 to 0.5 mg/kg loading dose followed by continuous infusion) has been used in critically ill neonates unable to tolerate enteral medication, but IV sildenafil availability varies by country.

Dr. Robin Steinhorn, a specialist in neonatal pulmonary hypertension, noted in a 2010 review: "Sildenafil fills a critical gap in PPHN management, particularly in low-resource settings where inhaled nitric oxide infrastructure does not exist" 13.

When Sildenafil Is Not Enough: Escalation Pathways

Children who do not achieve adequate hemodynamic or clinical response on sildenafil monotherapy may require escalation. The 2015 AHA/ATS guidelines outline a stepped approach 10:

Add an endothelin receptor antagonist. Bosentan is the most studied in children, with European approval for pediatric PAH. Its CYP3A4 induction effect lowers sildenafil levels, so clinical response must be monitored after adding bosentan.

Add a prostacyclin pathway agent. Epoprostenol (IV), treprostinil (SC, IV, or inhaled), or iloprost (inhaled) can be added in children with WHO functional class III or IV symptoms despite dual oral therapy.

Consider atrial septostomy or lung transplantation. For refractory cases, these interventions represent last-line options. Pediatric lung transplant waitlist mortality remains high, with median wait times of 6 to 12 months at many centers.

The starting dose for sildenafil in children weighing 8 to 20 kg remains 10 mg three times daily, and exceeding the recommended weight-based bands is not advised per the FDA's 2014 clarification, even when clinical response appears inadequate 7.